Figure 1.
p300 is expressed in both nucleus and cytoplasm Silencing of p300 leads to abrogation of p300 expression in both nucleus and cytoplasm.
Cells were grown on cover slips and transfected either with control siRNA (siCtrl) or p300 siRNA (si-p300) and after 48 hrs fixed as described in the methods section. Immunofluorescent staining was performed on the cells grown on cover slips using anti-p300 antibody (green). Nucleus was stained with DAPI (blue).
Figure 2.
p300 expression in melanoma patients.
(A) Representative images at 100× (upper panel) and 400× (lower panel) magnification of normal nevi (NN) and dysplastic nevi (DN) with strong and primary melanoma (PM) and metastatic melanoma (MM) with weak nuclear p300 staining. (B) Nuclear p300 staining is significantly decreased from normal and dysplastic nevi to melanoma by Kruskal-Wallis test. (C) Percentage of strong p300 staining in nuclei is significantly decreased from normal and dysplastic nevi to melanoma by χ2 test. (D) Cytoplasmic p300 staining is significantly increased from nevi to melanoma as studied by Kruskal-Wallis test. (E) Percentage of strong cytoplasmic staining is significantly increased from nevi to melanoma by χ2 test. **P<.01, ***P<.001.
Table 1.
Area under the ROC curve values for nuclear and cytoplasmic p300 expression.
Table 2.
p300 staining and clinicopathological characteristics of 392 melanoma patients.
Figure 3.
Nuclear p300 expression and 5-year patient survival.
Kaplan-Meier survival analyses of correlation between nuclear p300 expression and 5-year overall (left panels) and disease-specific (right panels) survival of melanoma patients in the training set (A and B), validation set (C and D), two sets combined (E and F), and in primary (G and H) and metastatic melanoma patients (I and J).
Figure 4.
Nulcear p300 expression and 10-year patient survival.
Kaplan-Meier survival analyses of correlation between nuclear p300 expression and 10-year overall (left panels) and disease-specific (right panels) survival of melanoma patients in all melanoma (A and B), primary melanoma (C and D), and metastatic melanoma (E and F).
Figure 5.
Cytoplasmic p300 expression and patient survival.
Kaplan-Meier survival analyses of correlation between cytoplasmic p300 expression, and overall (left panels) and disease-specific (right panels) 5-year (A and B) and 10-year (C and D) survival of melanoma patients.
Table 3.
Multivariate Cox regression analysis of overall and disease-specific survival in melanoma patients.